Treatment of COVID-19 Patients at a Medical College Hospital in Bangladesh
Muhammad AR Bhuyan, Eshita Ashab, Md Jahirul Haque, Syed Md M Hoque, AKM Faizul Huq, Md Atikul Islam, Nuzhat Choudhury, Reema A Alia, Musarrat Mahtab, Md Sakirul I Khan, Sheikh MF Akbar
Citation Information :
Bhuyan MA, Ashab E, Haque MJ, Hoque SM, Huq AF, Islam MA, Choudhury N, Alia RA, Mahtab M, Khan MS, Akbar SM. Treatment of COVID-19 Patients at a Medical College Hospital in Bangladesh. Euroasian J Hepatogastroenterol 2020; 10 (1):27-30.
Background and aim: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has induced a sense of panic around the world as the disease is highly contagious and has been spreading in full swing during last 5 months causing millions of COVID-19 patients and hundreds of thousands of deaths. Bangladesh, a country of 170 million people, is not an exception regarding COVID-19; it has reported several thousand COVID-19 patients with several hundred of deaths. This observational study has been planned to assess the scope and limitation of management strategy against COVID-19 patients in a medical college hospital of Bangladesh with available drugs in a real-life situation. Materials and methods: All patients in this cohort (N: 33) were positive for SARS-CoV-2 by polymerase chain reaction (PCR) and they attended the hospital with variable presenting symptoms those ranged from cough and fever to respiratory distress and pneumonia. As per the protocol, the patients were regularly evaluated for several parameters of COVID-19-related pathology. Before discharge, they were checked for SARS-CoV-2 for 2 consecutive times. The management strategy included standard of care (SoC) and administration of hydroxychloroquine and azythromycin, available in Bangladesh. Results: Out of total 33 patients, 1 patient died at day 4 day after admission. Two patients developed severe complications and were referred to tertiary hospital in Dhaka (2 and 3 days after admission), the capital of Bangladesh, where they recovered and were discharged from hospital after being SARS-CoV-2 negative. The rest 30 patients were discharged from the medical college hospital after being negative for SARS-CoV-2 in two subsequent assessments and improvement of their COVID-related symptoms. The average hospital stay of these patients was 14.5 days with a range of 10–24 days. Conclusion: It seems that most of the COVID-19 patients may be adequately managed by standard of care management with drug support. However, early diagnosis and hospitalization with adequate care may be important variables for better survival. These factors may be properly ensured if the patient burden remains at a palatable level in forthcoming days in Bangladesh.
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727–733. DOI: 10.1056/NEJMoa2001017.
Gorbalenya AE, Baker SC, Baric RS, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5:536–544. DOI: 10.1038/s41564-020-0695-z.
World Health Organization. Coronavirus disease (COVID-19) Pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019, May 11th 2020.
Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020;323(14):1406–1407. DOI: 10.1001/jama.2020.2565.
Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020;382(10):970–971. DOI: 10.1056/NEJMc2001468.
Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020;382(10):929–936. DOI: 10.1056/NEJMoa2001191.
Hoehl S, Rabenau H, Berger A, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N Engl J Med 2020;382(13):1278–1280. DOI: 10.1056/NEJMc2001899.
Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020;382(12):1177–1179. DOI: 10.1056/NEJMc2001737.
Lai C-C, Shih T-P, Ko W-C, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020;55(3):105924. DOI: 10.1016/j.ijantimicag.2020.105924.
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer 2018;6(1):56. DOI: 10.1186/s40425-018-0343-9.
Wan S, Yi Q, Fan S, et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol 2020;189(3):428–437. DOI: 10.1111/bjh.16659.
Steinbrook R. Contact tracing, testing, and control of COVID-19—learning from Taiwan. JAMA Intern Med 2020. DOI: 10.1001/jamainternmed.2020.2072.
IEDCR. https://www.iedcr.gov.bd/.
Million M, Lagier J-C, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 2020. 101738. DOI: 10.1016/j.tmaid.2020.101738.
La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis 2020;39(6):1059–1061. DOI: 10.1007/s10096-020-03913-9.
He HJ, Zhang W, Liang J, et al. Etiology and genetic evolution of canine coronavirus circulating in five provinces of China, during 2018-2019. Microb Pathog 2020;145:104209. DOI: 10.1016/j.micpath.2020.104209.
van Dorp L, Acman M, Richard D, et al. Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. Infect Genet Evol 2020;83:104351. DOI: 10.1016/j.meegid.2020.104351.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect 2020;80(6):607–613. DOI: 10.1016/j.jinf.2020.03.037.
